Soleno Therapeutics (SLNO) Common Equity (2016 - 2019)
Historic Common Equity for Soleno Therapeutics (SLNO) over the last 7 years, with Q3 2019 value amounting to $14.9 million.
- Soleno Therapeutics' Common Equity rose 478.7% to $14.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $14.9 million, marking a year-over-year increase of 478.7%. This contributed to the annual value of $30.4 million for FY2018, which is 1340.94% up from last year.
- As of Q3 2019, Soleno Therapeutics' Common Equity stood at $14.9 million, which was up 478.7% from $13.8 million recorded in Q2 2019.
- Soleno Therapeutics' Common Equity's 5-year high stood at $30.4 million during Q4 2018, with a 5-year trough of -$11.3 million in Q1 2015.
- Moreover, its 5-year median value for Common Equity was $14.2 million (2018), whereas its average is $12.8 million.
- In the last 5 years, Soleno Therapeutics' Common Equity soared by 92252.87% in 2017 and then tumbled by 4065.87% in 2018.
- Quarter analysis of 5 years shows Soleno Therapeutics' Common Equity stood at $3.2 million in 2015, then increased by 6.56% to $3.4 million in 2016, then skyrocketed by 680.65% to $26.8 million in 2017, then rose by 13.41% to $30.4 million in 2018, then plummeted by 51.06% to $14.9 million in 2019.
- Its Common Equity was $14.9 million in Q3 2019, compared to $13.8 million in Q2 2019 and $23.6 million in Q1 2019.